Of note, the treatment arsenal of HER2-positive breast cancer is rapidly evolving, with several agents (e.g., antibody–drug conjugates and novel tyrosine kinase inhibitors) which are being evaluated in the early-stage setting66 and may reshape the current biomarker landscape. Here, ERBB2 is linked to breast carcinoma.